A clinical trial update dated September 11, 2026 reports on a study titled "A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer." The trial, registered as NCT07335796, is listed in Phase 2. Its current status is active but not recruiting, meaning the study is ongoing but no longer enrolling new participants.
Degarelix is an approved compound being evaluated in this trial in combination with BMS986365 for people with prostate cancer. The registry entry does not provide efficacy or safety outcomes at this stage. No results have been posted in connection with this update.
This brief reflects only the status change recorded for the trial as of the listed date. It does not describe trial design details, endpoints, or any interim findings beyond what is stated in the registry record. Readers interested in the trial's full protocol and future results can consult the official ClinicalTrials.gov listing for updates as the study progresses.
For more background on this compound, see the degarelix overview.